Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children

Clinical Infectious Diseases

Volumn 43, Issue 2, 2006, Pages 243-252

  Resino, Salvador ^a,b   Resino, Rosa ^a   Bellón, José Ma ^a   Micheloud, Dariela ^a   Gutiérrez, Ma Dolores Gurbindo ^b   De José, Ma Isabel ^c   Ramos, José Tomás ^d   Fontelos, Pablo Martín ^c   Ciria, Luis ^e   Muñoz Fernández, Ma Ángeles ^a  

^a Laboratorio de Biología   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHILD; CHILD HOSPITALIZATION; CLINICAL PROTOCOL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33745686071     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/505213     Document Type: Article

References (39)

1. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988; 319:889-96.
2. Fraaij PL, Verweel G, van Rossum AM, et al. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:604-8.
3. Berk DR, Falkovitz-Halpern MS, Hill DW, et al. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA 2005; 293:2221-31.
4. Teglas JP, Mayaux MJ, Blanche S. Antiretroviral therapy and mortality among children with perinatal HIV infection. JAMA 2000; 284:2871-2.
5. Storm DS, Boland MG, Gortmaker SL, et al. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection. Pediatrics 2005; 115:e173-82.
6. Tovo PA, de Martino M, Gabiano C, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children. Lancet 1992; 339:1249-53.
7. de Martino M, Tovo PA, Galli L, et al. Prognostic significance of immunologic changes in 675 infants perinatally exposed to human immunodeficiency virus. The Italian Register for Human Immunodeficiency Virus Infection in Children. J Pediatr 1991; 119:702-9.
8. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999; 28:1109-18.
9. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999; 341:1874-81.
10. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345:1522-8.
11. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000; 284:190-7.
12. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327:1019.
13. Munoz-Fernandez MA, Obregon E, Navarro J, et al. Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection. Pediatr Res 1996; 40:597-602.
14. Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR CDC Surveill Summ 1994; 43:1-10. Available at: http://www.cdc.gov/ mmwr/preview/mmwrhtml/00032890.htm.
15. Centers for Disease Control and Prevention. Revised classification system for HIV-1 infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17):1-19.
16. Centers for Disease Control and Prevention. Guidelines for use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998; 47:1-43.
17. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Recomm Rep 1994; 43:1-20.
18. Sharland M, Gibb D, Giaquinto C. Current evidence for the use of paediatric antiretroviral therapy-a PENTA analysis. Paediatric European Network for the Treatment of AIDS Steering Committee. Eur J Pediatr 2000; 159:649-56.
19. Centers for Disease Control and Prevention. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Recomm Rep 1992; 41:1-11.
20. Resino S, Bellón J, Resino R, et al. Extensive implementation of highly active antiretroviral therapy shows great effectiveness on the survival and surrogate markers in vertically HIV-infected children. Clin Infect Dis 2004; 38:1605-12.
21. Munoz A, Gange SJ, Jacobson LP. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS 2000; 14:754-6.
22. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-503.
23. Sidi A, Lobato EB, Cohen JA. The American Society of Anesthesiologists' Physical Status: category V revisited. J Clin Anesth 2000; 12:328-34.
24. Keats AS. The ASA classification of physical status-a recapitulation. Anesthesiology 1978; 49:233-6.
25. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362:1267-74.
26. Butler KM, Husson RN, Balis FM, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 324:137-44.
27. McKinney RE Jr, Maha MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med 1991; 324:1018-25.
28. Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. J Clin Invest 1997; 99:2837-41.
29. Resino S, Correa R, Bellon J, Sanchez-Ramon S, Muñoz-Fernandez M. Characterizing immune reconstitution after long-term HAART in pediatric AIDS. AIDS Res Hum Retrovir 2002; 18:1395-406.
30. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15:347-55.
31. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:143-52.
32. Mocroft A, Barry S, Sabin CA, et al. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. AIDS 1999; 13:1255-61.
33. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40:161-8.
34. Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39:725-31.
35. Resino S, Resino R, Micheloud D, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis 2006; 42:862-9.
36. Lindegren ML, Byers RH Jr, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999; 282:531-8.
37. HIV-infected pregnant women and vertical transmission in Europe since 1986: European collaborative study. AIDS 2001; 15:761-70.
38. Gray L, Newell ML, Thorne C, Peckham C, Levy J. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics 2001; 108:116-22.
39. Blanche S, Newell ML, Mayaux MJ, et al. Morbidity and mortality in European children vertically infected by HIV-1. The French Pediatric HIV Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:442-50.